在Astra Zeneca COVID-19疫苗后发生血栓栓塞:不总是PF4-抗体介导的
Sascha d'Almeida1, Sinisa Markovic1, Patrick Hermann2
1Department of Medicine II, Ulm University Medical Center, Ulm, Germany.
Human vaccines & immunotherapeutics
|September 1, 2023
概括
阿斯特拉泽内卡公司
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 血栓形成的原因之一是血栓形成.
背景情况:
- 关于AstraZeneca的AZD1222疫苗安全性的2021年讨论被血栓栓塞事件加剧.
- 据报道,在接种疫苗后发生了血栓栓塞事件,包括肺栓塞和门静脉血栓症.
研究的目的:
- 在接种AZD1222疫苗后报告血栓栓塞事件的病例.
- 调查与这些事件相关的潜在机制和患者特征.
主要方法:
- 一系列病例报告了5名男性患者 (30-60岁) 用AZD1222接种疫苗.
- 临床数据收集包括事件时间表,血小板计数,抗体水平和PF4抗体存在.
主要成果:
- 五名患者在接种疫苗后两周内发生了血栓栓塞事件 (肺栓塞,门静脉血栓症).
- 三名患者呈现出血小板缩和低抗斯派克蛋白抗体水平;一个有可检测的抗PF4抗体.
- 人们怀疑异构的机制,包括疫苗诱导的原血栓性免疫血栓性缺血症 (VIPIT).
结论:
- 需要进一步收集和报告病例,以了解与年龄相关的风险与AZD1222疫苗的SARS-CoV-2免疫益处.
- 研究结果强调需要保持警,对疫苗安全性和未来流行病的潜在不良事件进行进一步研究.
关键词:
AZD122222 这是一个很好的选择.这是COVID-19疫苗.VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT VIPIT这就是VITT VITT VITT.介腹静脉血栓形成的中枢静脉血栓肺栓塞 肺栓塞是一种肺栓塞.尖子蛋白质是什么?脊髓静脉血栓形成的原因血栓塞栓症 血栓塞栓症 血栓塞栓症年轻的男性年轻人相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Venous Thrombosis I: Introduction
12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
Anticoagulant Drugs: Low-Molecular-Weight Heparins
749
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
749
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
Disorders of Hemostasis
989
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
989
Pulmonary Embolism I: Introduction
7
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
7


